Can Cannabinoids Help Treat ADHD? A Review of the Emerging Evidence
A review of the literature finds that people with ADHD are at higher risk for cannabis dependence and may self-medicate with it, while early evidence suggests CBD may have therapeutic potential through dopamine and norepinephrine modulation.
Quick Facts
What This Study Found
Individuals with ADHD have elevated risk for substance use and cannabis dependence. Some may use cannabis to manage anxiety or medication side effects. Both in vivo and clinical investigations suggest cannabinoids, particularly CBD, may have therapeutic potential in ADHD, possibly through modulation of dopaminergic and noradrenergic systems.
Key Numbers
Review covers epidemiological data on ADHD-cannabis co-occurrence, self-medication patterns, and multiple proposed pharmacological mechanisms including dopamine and norepinephrine modulation.
How They Did This
Comprehensive narrative review of literature on cannabinoid effects in ADHD, examining epidemiological associations, self-medication patterns, preclinical evidence, clinical studies, and proposed pharmacological mechanisms.
Why This Research Matters
ADHD affects millions of people, and existing medications have significant side effects and limitations. If cannabinoids (particularly CBD) prove effective, they could offer a new treatment option for a population that already uses cannabis at elevated rates.
The Bigger Picture
The intersection of ADHD and cannabis use is a growing clinical reality. Understanding whether cannabis use in this population is self-medication versus additional risk is essential for both ADHD treatment and cannabis policy.
What This Study Doesn't Tell Us
Narrative review with limited clinical evidence. Most mechanistic evidence is from animal studies. No large-scale RCTs of cannabinoids for ADHD exist. The review cannot determine whether cannabis use in ADHD is beneficial or harmful.
Questions This Raises
- ?Could CBD specifically treat ADHD symptoms without the risks of THC?
- ?Would controlled clinical trials show benefit, or would the risks outweigh any therapeutic effect?
Trust & Context
- Key Stat:
- People with ADHD are at higher risk for cannabis dependence
- Evidence Grade:
- Narrative review compiling limited evidence. No large clinical trials exist for cannabinoids in ADHD.
- Study Age:
- Published in 2025.
- Original Title:
- Cannabinoids and ADHD: a New Frontier in Neuropharmacology?
- Published In:
- Journal of molecular neuroscience : MN, 75(4), 146 (2025)
- Authors:
- Mavaddat, Helia, Fouladi, Abtin, Kashani, Ayeh Sabbagh, Khayatan, Illia, Andarzbaksh, Kamyab, Razavi, Seyed Mehrad, Rezazadeh, Amir
- Database ID:
- RTHC-07088
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Should people with ADHD use cannabis?
The review highlights both risks (higher dependence vulnerability) and potential benefits (symptom management). There is not enough clinical evidence to recommend cannabis for ADHD, and the higher dependence risk in this population is a significant concern.
Why might CBD help ADHD?
CBD may modulate dopamine and norepinephrine systems that are dysregulated in ADHD. However, this is based primarily on preclinical evidence and has not been confirmed in large human trials.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-07088APA
Mavaddat, Helia; Fouladi, Abtin; Kashani, Ayeh Sabbagh; Khayatan, Illia; Andarzbaksh, Kamyab; Razavi, Seyed Mehrad; Rezazadeh, Amir. (2025). Cannabinoids and ADHD: a New Frontier in Neuropharmacology?. Journal of molecular neuroscience : MN, 75(4), 146. https://doi.org/10.1007/s12031-025-02435-3
MLA
Mavaddat, Helia, et al. "Cannabinoids and ADHD: a New Frontier in Neuropharmacology?." Journal of molecular neuroscience : MN, 2025. https://doi.org/10.1007/s12031-025-02435-3
RethinkTHC
RethinkTHC Research Database. "Cannabinoids and ADHD: a New Frontier in Neuropharmacology?" RTHC-07088. Retrieved from https://rethinkthc.com/research/mavaddat-2025-cannabinoids-and-adhd-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.